Standard BioTools receives $30M Illumina buyout, sells mass cytometry for $5M note

Filed July 28, 2026 · Period ending July 24, 2026 · ~2 min read

Key Changes

• high

  Received $30M cash from Illumina to terminate earnout rights and royalty agreements from the January 2026 SomaLogic sale, converting uncertain future payments into immediate cash that will increase pro forma net cash in the pending Treeline merger.

  Item 1.01 verify on EDGAR →
• high

  Agreed to sell mass cytometry business to Multiplex Bio for $5M five-year note at 6% interest (no upfront cash) plus potential $5M earnout, with closing contingent on shareholder approval and completion of the Treeline merger.

  Item 1.01 verify on EDGAR →
• medium

  May be required to provide up to $10M working capital loan to Multiplex Bio at closing if the buyer cannot secure third-party financing, creating potential additional cash outflow and credit risk.

  Item 1.01 verify on EDGAR →